Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer
暂无分享,去创建一个
Mengzhong Liu | Guixiang Liao | Yawei Yuan | Jie Lin | Muhammad Khan | Yunhong Tian | Rong Li | Yingying Liang | R. Li | Rong Li
[1] T. Mok,et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. , 2018, Journal of Clinical Oncology.
[2] Laurence Zitvogel,et al. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies , 2018, Science.
[3] R. Ramirez,et al. The Role of Checkpoint Inhibition in Non-Small Cell Lung Cancer. , 2017, The Ochsner journal.
[4] Percy Lee,et al. Radiotherapy: the key to immunotherapy ignition? , 2017, Oncotarget.
[5] Minghui Zhang,et al. PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis , 2017, Scientific Reports.
[6] P. Stephens,et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.
[7] M. Socinski,et al. First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[8] P. Jänne,et al. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Li,et al. PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer , 2017, Oncotarget.
[10] M. Ahn,et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] J. Soria,et al. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? , 2017, BMC Medicine.
[12] E. Richardsen,et al. Assessing PDL‐1 and PD‐1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach , 2017, Clinical lung cancer.
[13] C. Gridelli,et al. The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer. , 2017, Current clinical pharmacology.
[14] Carlos Barrios,et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.
[15] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[16] O. Abdel-Rahman. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. , 2016, Critical reviews in oncology/hematology.
[17] Keunchil Park,et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.
[18] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[19] Gideon Blumenthal,et al. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy , 2016, The oncologist.
[20] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[21] J. Yi,et al. 14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR) , 2015 .
[22] R. McCormack,et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). , 2015, American journal of cancer research.
[23] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[24] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[25] Yan Liu,et al. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation , 2015, Journal of Translational Medicine.
[26] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[27] Ning Li,et al. Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer , 2014, PloS one.
[28] Li Zhang,et al. The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer , 2014, Chinese journal of cancer.
[29] M. Atkins,et al. PD-1 as a potential target in cancer therapy , 2013, Cancer medicine.
[30] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[31] J. Allison,et al. Checkpoint blockade in cancer immunotherapy. , 2007, Advances in immunology.
[32] S. Jabbour,et al. Current state of immunotherapy for non-small cell lung cancer. , 2007, Translational lung cancer research.
[33] Miklos Pless,et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. Shibuya,et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.